-1280x720-800x450.jpg)
- Avecho Biotechnology (AVE) begins dosing volunteers for its clinical trial measuring CBD absorption
- The Australian Phase I pharmacokinetic study is designed to test the absorption of cannabidiol (CBD) from its soft-gel product, TPM
- The first dose has been completed by sixteen healthy volunteers, with the second scheduled for October 9, after which blood samples will be analysed
- High level results are expected in December, with the study to assist Avecho’s ongoing research and open the possibility of commercial partnerships
- Avecho Biotechnology is up 11.1 per cent, trading at 2 cents at 4:50 pm AEDT.
Avecho Biotechnology (AVE) has begun dosing volunteers for its clinical trial measuring CBD absorption.
Avecho’s Australian Phase I pharmacokinetic study has been designed to test the absorption of cannabidiol (CBD) from its soft-gel product, TPM.
This follows a previous trial that showed Avecho’s formulation increased the oral bioavailability of CBD in animal models when compared to standard CBD preparations.
The dosing marks the first CBD study Avecho has undertaken in humans. The study will see sixteen healthy volunteers receive 75 milligrams of the company’s CBD soft-gel product in two separate doses over a period of two weeks.
The first dose was completed on Saturday in Adelaide, with no adverse events of concern reported. The second dose is scheduled for October 9. Blood samples will be analysed and the results will be used to investigate a range of standard pharmacokinetic variables.
“While we won’t have the CBD absorption results until later in the year, it is already good to see that the CBD dose was well tolerated by subjects,” said Avecho CEO, Dr Paul Gavin.
High level results are expected in December, which the company hopes will assist Avecho’s ongoing research and open the possibility of commercial partnerships.
Avecho Biotechnology was up 11.1 per cent, rounding off the day at 2 cents.